LOS ANGELES–(BUSINESS WIRE)— Turn Therapeutics announced a significant breakthrough in the treatment of atopic dermatitis, revealing that their new candidate markedly reduced disease severity in a widely cited in-vivo model.
After a seven-day induction period, the mean severity score across all groups was recorded at 3.3 on the Investigator’s Static Global Assessment (ISGA) scale, which assesses atopic dermatitis severity from 0 (completely clear) to 4 (severe eczema).
Following a subsequent seven-day treatment phase, Turn Therapeutics’ candidate achieved a reduction in ISGA score to 1.44, equating to a 57% improvement. In comparison, the placebo group only saw a reduction to 3.0, or a 10% improvement. This candidate’s underlying formula is already approved by the U.S. Food and Drug Administration for its safety in humans, showing no cytotoxicity or sensitization.
“Individuals suffering from atopic dermatitis are in urgent need of safe, effective, non-steroidal, and non-injectable treatment options,” stated Bradley Burnam, founder and CEO of Turn Therapeutics. “With a reduction of 1.89 points on the ISGA scale within just seven days, along with confirmed inflammatory markers post-induction, we anticipate uncovering significant immunological activity with our atopic dermatitis candidate.”
Further details and study results can be accessed at turntherapeutics.com.
About Turn Therapeutics
Turn Therapeutics is dedicated to pharmaceutical and medical device innovation, particularly in advanced wound and dermatologic care. The company’s technology addresses conditions with limited safe and effective treatments, such as moderate to severe eczema and onychomycosis. Guided by medical experts, Turn Therapeutics’ flagship formula has shown promising efficacy across various indications. For more information, visit turntherapeutics.com.
Forward-Looking Statements Disclaimer
This press release may contain forward-looking statements based on current management expectations, which involve risks and uncertainties that could cause actual results to differ materially.
Related Topics:
